Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 18/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22328205 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL11645370 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL11119241 | 0.73 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL19258707 | 0.71 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL85820 | 0.70 | GRM5 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL468941 | 0.70 | — | — | |
| SCHEMBL1209106 | 0.70 | — | — | |
| Isouron SCHEMBL11230193 | 0.69 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL11401437 | 0.69 | FDPS (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 | |
| SCHEMBL13430874 | 0.69 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | SMN1; SMN2 2298/4885NPC1 859/4885RAB9A 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.